New lupus drug trial seeks to tame rogue immune system
NCT ID NCT07348055
Summary
This early-stage trial is testing a new injection called GR1803 in people with systemic lupus erythematosus (SLE), a serious autoimmune disease. The main goal is to see if the treatment is safe and if it can help control the disease. The study will enroll 44 participants who have active lupus despite taking standard medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.